Frankfurt
23.10.25 | 08:09
0,156 Euro
-1,27 % -0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | BioPorto A/S: Grant of Warrants | 1 | GlobeNewswire (USA) | ||
| BIOPORTO Aktie jetzt für 0€ handeln | |||||
| 28.08. | BioPorto A/S: ProNephro AKI (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto's collaboration with Roche Diagnostics. | 5 | GlobeNewswire (USA) | ||
| 15.08. | BioPorto A/S: BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. | 126 | GlobeNewswire (Europe) | August 15, 2025Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen... ► Artikel lesen | |
| 29.07. | BioPorto A/S to host an investor webcast on the results for the first half of 2025 | 1 | GlobeNewswire (USA) | ||
| 28.07. | BioPorto A/S: BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. | 1 | GlobeNewswire (USA) | ||
| 27.06. | BioPorto A/S: Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US | 262 | GlobeNewswire (Europe) | June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 - BioPorto A/S ("BioPorto"... ► Artikel lesen | |
| 12.06. | BioPorto A/S: Grant of Warrants | 1 | GlobeNewswire (USA) | ||
| 10.06. | BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy | 435 | GlobeNewswire (Europe) | June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 08.05. | BioPorto A/S: Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. | 192 | GlobeNewswire (Europe) | May 8, 2025Announcement no. 15Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update... ► Artikel lesen | |
| 28.04. | BioPorto A/S: Grant of Warrants | 2 | GlobeNewswire (USA) | ||
| 28.04. | BioPorto A/S to host first quarter 2025 earnings webcast for investors | 1 | GlobeNewswire (USA) | ||
| 25.04. | BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes | 393 | GlobeNewswire (Europe) | April 25, 2025Announcement no. 12BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes Completion of share capital increase COPENHAGEN, DENMARK, April 25... ► Artikel lesen | |
| 11.04. | BioPorto A/S: Resolutions of the Annual General Meeting | 167 | GlobeNewswire (Europe) | April 11, 2025 Announcement no. 9 Resolutions of the Annual General Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 11, 2025, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH: BIOPOR)... ► Artikel lesen | |
| 20.03. | BioPorto A/S: BioPorto announces the Annual Report for 2024 | 201 | GlobeNewswire (Europe) | March 20, 2025Announcement no. 06BioPorto announces the Annual Report for 2024 Copenhagen, Denmark, March 20, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or company) (CPH:BIOPOR), an in vitro... ► Artikel lesen | |
| 19.03. | BioPorto A/S: BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 | 107 | GlobeNewswire (Europe) | March 19, 2025Announcement no. 05BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 Copenhagen, Denmark, March 19, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or Company)... ► Artikel lesen | |
| 29.01. | BioPorto A/S appoints new interim Chairman of the Board | 336 | GlobeNewswire (Europe) | January 29, 2025Announcement no. 02 BioPorto A/S appoints new interim Chairman of the Board COPENHAGEN, DENMARK, January 29, 2025, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto... ► Artikel lesen | |
| 06.01. | BioPorto A/S: Preliminary Financial Figures for the 2024 Fiscal Year | 148 | GlobeNewswire (Europe) | January 6, 2025 Announcement no. 01 Preliminary Financial Figures for the 2024 Fiscal Year COPENHAGEN, DENMARK, January 6, 2025, (GLOBE NEWSWIRE) - BioPorto A/S CVR-no. 17500317 (BioPorto or Company)... ► Artikel lesen | |
| 14.11.24 | BioPorto A/S: BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 | 194 | GlobeNewswire (Europe) | November 14, 2024Announcement no. 22 BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 Revenue growth and strategic execution COPENHAGEN,... ► Artikel lesen | |
| 28.10.24 | BioPorto A/S: BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests | 271 | GlobeNewswire (Europe) | 28 October 2024Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,25 | -1,53 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
| EVOTEC | 6,812 | +1,28 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| BB BIOTECH | 41,650 | -1,19 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| MEDIGENE | 0,055 | -14,55 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 42,045 | -0,05 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,644 | +0,22 % | Pharmaindustrie: Aktientausch von Curevac zu Biontech ab sofort möglich | ||
| MODERNA | 22,650 | -2,05 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
| PAION | 0,017 | -24,11 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
| VALNEVA | 4,136 | 0,00 % | Valneva-Aktie unter Druck - Anleger verlieren vorerst das Vertrauen in den Impfstoffhersteller! | ||
| AMGEN | 253,25 | -0,73 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| EPIGENOMICS | 0,880 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,150 | -1,85 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| BIOGEN | 127,45 | +0,12 % | Biogen Inc.: Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 | Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality... ► Artikel lesen | |
| BIOFRONTERA | 2,650 | +1,14 % | Biofrontera Inc. Closes Purchase of All Ameluz and RhodoLED US Assets from Biofrontera AG | Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment... ► Artikel lesen | |
| HEIDELBERG PHARMA | 3,130 | +7,56 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung des multiplen Myeloms | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Fast-Track-Status von der US FDA für seinen führenden ADC-Kandidaten HDP-101 zur Behandlung... ► Artikel lesen |
Das Unternehmen BIOPORTO A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,156 Euro und damit -1,27 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOPORTO A/S finden Sie auf Wallstreet Online.